Shenzhen, Guangdong, China In 1999 was created BGI Genomics, which is appeared as Corporate Investor. The fund was located in Asia if to be more exact in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.
For fund there is a match between the location of its establishment and the land of its numerous investments - China. The fund has no specific favorite in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Genedock, F&S Pharmatech, Congenica Besides, a startup needs to be aged 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Chemical.
The fund was created by Huanming Yang.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the BGI Genomics, startups are often financed by Cambridge Innovation Capital, Amadeus Capital Partners, Puhua Capital. The meaningful sponsors for the fund in investment in the same round are Green Pine Capital Partners, Volcanics Venture, UEC Group. In the next rounds fund is usually obtained by Volcanics Venture, UEC Group, Parkwalk Advisors.
The top activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. Speaking about the real fund results, this Corporate Investor is 23 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year.
Related Funds
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Gooal Gene | $1M | 21 Nov 2019 | Wuhan, Hubei, China | ||
Beijing Gene+ Technology | $28M | 30 Sep 2019 | Changping District, Beijing, China | ||
Geneplus-Beijing Co. Ltd. | $7M | 15 Jan 2019 | - | ||
| $3M | 07 Dec 2018 | Futian District, Guangdong Province, China | |||
F&S Pharmatech | $7M | 30 Sep 2018 | Xuanwu District, Jiangsu, China | ||
Genedock | $7M | 06 Aug 2018 | Dongcheng District, Beijing, China | ||
Congenica | 27 Apr 2017 | Cambridge, England, United Kingdom | |||
Beijing Gene+ Technology | $30M | 14 Sep 2016 | Changping District, Beijing, China | ||
Geneplus-Beijing Co. Ltd. | $30M | 09 Sep 2016 | - |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Gooal Gene | $1M | 21 Nov 2019 | Wuhan, Hubei, China | ||
Beijing Gene+ Technology | $28M | 30 Sep 2019 | Changping District, Beijing, China | ||
Geneplus-Beijing Co. Ltd. | $7M | 15 Jan 2019 | - | ||
| $3M | 07 Dec 2018 | Futian District, Guangdong Province, China | |||
F&S Pharmatech | $7M | 30 Sep 2018 | Xuanwu District, Jiangsu, China | ||
Genedock | $7M | 06 Aug 2018 | Dongcheng District, Beijing, China | ||
Congenica | 27 Apr 2017 | Cambridge, England, United Kingdom | |||
Beijing Gene+ Technology | $30M | 14 Sep 2016 | Changping District, Beijing, China | ||
Geneplus-Beijing Co. Ltd. | $30M | 09 Sep 2016 | - |
